vs
ONTO INNOVATION INC.（ONTO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
ONTO INNOVATION INC.的季度营收约是再鼎医药的1.7倍（$218.2M vs $127.1M），再鼎医药同比增速更快（17.1% vs -13.5%），ONTO INNOVATION INC.自由现金流更多（$82.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.6%）
Onto Innovation是一家美国半导体企业，2019年由Rudolph Technologies与Nanometrics合并组建，为微电子制造行业提供生产工艺、工艺控制相关设备及配套软件解决方案，是全球半导体制造支撑领域的重要供应商。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ONTO vs ZLAB — 直观对比
营收规模更大
ONTO
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出30.6%
-13.5%
自由现金流更多
ONTO
多$108.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $218.2M | $127.1M |
| 净利润 | $28.2M | — |
| 毛利率 | 50.7% | 51.0% |
| 营业利润率 | 10.9% | -54.6% |
| 净利率 | 12.9% | — |
| 营收同比 | -13.5% | 17.1% |
| 净利润同比 | -46.8% | — |
| 每股收益（稀释后） | $0.57 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ONTOZLAB
| Q4 25 | — | $127.1M | ||
| Q3 25 | $218.2M | $115.4M | ||
| Q2 25 | $253.6M | $109.1M | ||
| Q1 25 | $266.6M | $105.7M | ||
| Q4 24 | $263.9M | $108.5M | ||
| Q3 24 | $252.2M | $101.8M | ||
| Q2 24 | $242.3M | $100.1M | ||
| Q1 24 | $228.8M | $87.1M |
净利润ONTOZLAB
| Q4 25 | — | — | ||
| Q3 25 | $28.2M | $-36.0M | ||
| Q2 25 | $33.9M | $-40.7M | ||
| Q1 25 | $64.1M | $-48.4M | ||
| Q4 24 | $48.8M | — | ||
| Q3 24 | $53.1M | $-41.7M | ||
| Q2 24 | $52.9M | $-80.3M | ||
| Q1 24 | $46.9M | $-53.5M |
毛利率ONTOZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | 50.7% | 59.5% | ||
| Q2 25 | 48.2% | 60.6% | ||
| Q1 25 | 53.7% | 63.6% | ||
| Q4 24 | 50.2% | 61.5% | ||
| Q3 24 | 54.1% | 64.1% | ||
| Q2 24 | 52.9% | 64.9% | ||
| Q1 24 | 51.7% | 61.4% |
营业利润率ONTOZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 10.9% | -42.3% | ||
| Q2 25 | 12.7% | -50.3% | ||
| Q1 25 | 23.7% | -53.3% | ||
| Q4 24 | 16.1% | -62.6% | ||
| Q3 24 | 21.0% | -66.6% | ||
| Q2 24 | 20.2% | -76.0% | ||
| Q1 24 | 18.7% | -80.7% |
净利率ONTOZLAB
| Q4 25 | — | — | ||
| Q3 25 | 12.9% | -31.2% | ||
| Q2 25 | 13.4% | -37.3% | ||
| Q1 25 | 24.0% | -45.8% | ||
| Q4 24 | 18.5% | — | ||
| Q3 24 | 21.0% | -40.9% | ||
| Q2 24 | 21.9% | -80.2% | ||
| Q1 24 | 20.5% | -61.4% |
每股收益（稀释后）ONTOZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.57 | $-0.03 | ||
| Q2 25 | $0.69 | $-0.04 | ||
| Q1 25 | $1.30 | $-0.04 | ||
| Q4 24 | $0.98 | $-0.09 | ||
| Q3 24 | $1.07 | $-0.04 | ||
| Q2 24 | $1.07 | $-0.08 | ||
| Q1 24 | $0.94 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $603.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $715.5M |
| 总资产 | $2.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ONTOZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | $603.1M | $717.2M | ||
| Q2 25 | $217.5M | $732.2M | ||
| Q1 25 | $203.7M | $757.3M | ||
| Q4 24 | $212.9M | $779.7M | ||
| Q3 24 | $188.7M | $616.1M | ||
| Q2 24 | $172.6M | $630.0M | ||
| Q1 24 | $190.9M | $650.8M |
股东权益ONTOZLAB
| Q4 25 | — | $715.5M | ||
| Q3 25 | $2.0B | $759.9M | ||
| Q2 25 | $2.0B | $791.7M | ||
| Q1 25 | $1.9B | $810.8M | ||
| Q4 24 | $1.9B | $840.9M | ||
| Q3 24 | $1.9B | $667.7M | ||
| Q2 24 | $1.8B | $704.2M | ||
| Q1 24 | $1.8B | $762.2M |
总资产ONTOZLAB
| Q4 25 | — | $1.2B | ||
| Q3 25 | $2.2B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.1B | $1.2B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.1B | $985.3M | ||
| Q2 24 | $2.0B | $987.4M | ||
| Q1 24 | $2.0B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $83.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $82.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 37.6% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.95× | — |
| 过去12个月自由现金流最近4个季度 | $261.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ONTOZLAB
| Q4 25 | — | $-26.0M | ||
| Q3 25 | $83.4M | $-32.0M | ||
| Q2 25 | $57.9M | $-31.0M | ||
| Q1 25 | $92.0M | $-61.7M | ||
| Q4 24 | $56.0M | $-55.8M | ||
| Q3 24 | $67.2M | $-26.8M | ||
| Q2 24 | $65.3M | $-42.2M | ||
| Q1 24 | $57.1M | $-90.1M |
自由现金流ONTOZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $82.0M | $-35.0M | ||
| Q2 25 | $44.2M | $-33.9M | ||
| Q1 25 | $83.7M | $-63.2M | ||
| Q4 24 | $51.4M | $-58.4M | ||
| Q3 24 | $59.2M | $-28.2M | ||
| Q2 24 | $53.0M | $-42.9M | ||
| Q1 24 | $50.2M | $-91.1M |
自由现金流率ONTOZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | 37.6% | -30.4% | ||
| Q2 25 | 17.4% | -31.1% | ||
| Q1 25 | 31.4% | -59.9% | ||
| Q4 24 | 19.5% | -53.8% | ||
| Q3 24 | 23.5% | -27.7% | ||
| Q2 24 | 21.9% | -42.9% | ||
| Q1 24 | 21.9% | -104.5% |
资本支出强度ONTOZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 5.4% | 2.6% | ||
| Q1 25 | 3.1% | 1.5% | ||
| Q4 24 | 1.8% | 2.4% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 5.1% | 0.7% | ||
| Q1 24 | 3.0% | 1.1% |
现金转化率ONTOZLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.23× | — | ||
| Q1 24 | 1.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ONTO
| Systems And Software Revenue | $173.8M | 80% |
| Parts Revenue | $23.9M | 11% |
| Service Revenue | $20.5M | 9% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
